References Anemia, Pernicious- Rare Disease Database, NORD, National Organization for Rare Disorders [Internet]
Ganorkar stated, "Improving access to GLP-1 treatments in the coming years may be a key driver for the Indian pharmaceutical industry, helping address the growing burden of lifestyle diseases such as obesity and diabetes." He noted that combining these treatments with AI-enabled digital tools for early disease detection, monitoring, and personalized medicine choices could drive innovation focused on accessibility, affordability, and better patient outcomes
With growing human research, it stands as a promising counterpart to non-enzymatic antioxidants like glutathione in supporting health
frequent pauses undermine weight loss durability
Continuous Monitoring : Regular follow-ups and progress evaluations ensure treatment safety and effectiveness